TTY BIOPHARM COMPANY LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 76 TWD | -1.81% |
|
-2.81% | -5.47% |
| Mar. 14 | TTY Biopharm Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 08 | TTY Biopharm Company Limited Announces Change of CFO and Financial Officer | CI |
| Sales 2024 * | 5.8B 178M | Sales 2025 * | 6.3B 194M | Capitalization | 18.9B 581M |
|---|---|---|---|---|---|
| Net income 2024 * | 1.35B 41.41M | Net income 2025 * | 1.66B 51.01M | EV / Sales 2024 * | 3.26 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3 x |
| P/E ratio 2024 * |
14
x | P/E ratio 2025 * |
11.4
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.72% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.81% | ||
| 1 week | -2.81% | ||
| Current month | -2.81% | ||
| 1 month | -6.29% | ||
| 3 months | -2.31% | ||
| 6 months | -3.80% | ||
| Current year | -5.47% |
1 week
75.70
78.30
1 month
75.7082.30
Current year
75.7083.00
1 year
74.3087.00
3 years
66.2097.50
5 years
54.2097.50
10 years
49.80137.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sara Hou
CEO | Chief Executive Officer | - | 22-04-17 |
Guo Jiang Zhang
DFI | Director of Finance/CFO | - | 15-12-30 |
Shu Fen Huang
CMP | Compliance Officer | - | 22-04-17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wen Hua Chang
BRD | Director/Board Member | - | 95-07-23 |
Hsiu Chi Chang
BRD | Director/Board Member | - | 16-06-23 |
Tzu Chiang Yang
BRD | Director/Board Member | 68 | 16-06-23 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | -1.55% | - | |
| 0.00% | 34 M€ | +1.25% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 76 | -1.81% | 1 467 714 |
| 24-04-18 | 77.4 | +0.39% | 442,676 |
| 24-04-17 | 77.1 | +0.26% | 400,768 |
| 24-04-16 | 76.9 | -1.41% | 1,138,727 |
| 24-04-15 | 78 | -0.26% | 646,392 |
End-of-day quote Taipei Exchange, April 18, 2024
More quotes
TTY Biopharm Co Ltd is a Taiwan-based company mainly engaged in the research, development, manufacture and sale of pharmaceutical preparations. The Company mainly operates through six business segments including Cancer Drug segment, Healthcare segment, Anti-Infective Drug segment, Domestic Cardiovascular and Gastrointestinal Drug segment, Mainland Medical Drug segment and the Other segment. The main products include oncology medicines, anti-infective medicines and health care medicines. Oncology medicines are mainly anti-cancer and auxiliary drugs. Anti-infective medicines are mainly back-line antimicrobial agents and influenza vaccines. Medical and health care medicines are mainly gastrointestinal health care, bone health care, metabolic health care, infection treatment drugs. The Company distributes its products in domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-05-09
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
76
TWD
Average target price
86.5
TWD
Spread / Average Target
+13.82%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.47% | 593M | |
| +24.60% | 672B | |
| +24.08% | 550B | |
| -5.63% | 351B | |
| +15.37% | 317B | |
| +7.38% | 292B | |
| +3.26% | 211B | |
| +0.78% | 203B | |
| -9.69% | 144B | |
| -6.63% | 141B |
- Stock Market
- Equities
- 4105 Stock
